It just eliminates regulated access.

Absolutely.

And the growth of that illicit market is an existing public health threat that we've urged FDA to attend to.

We call our proposal guardrails.

We've also spoken of it, as you just have, as sort of a third way, neither blanket prohibition nor unrestricted compounding of these substances.

And our aim is a responsible pathway that is... only for patient-specific compounding under Section 503A, and that has an informed patient and also patient safety in mind.

Our guardrails include qualified API sourcing, and that's really one of the more important planks in the four or five guardrails that we have proposed.

It was not, yeah.

It just eliminates regulated access.

Absolutely.

And the growth of that illicit market is an existing public health threat that we've urged FDA to attend to.

We call our proposal guardrails.

We've also spoken of it, as you just have, as sort of a third way, neither blanket prohibition nor unrestricted compounding of these substances.

And our aim is a responsible pathway that is... only for patient-specific compounding under Section 503A, and that has an informed patient and also patient safety in mind.

Our guardrails include qualified API sourcing, and that's really one of the more important planks in the four or five guardrails that we have proposed.

It was not, yeah.